Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin plus aspirin versus atorvastatin alone in cirrhosis
IRCT20231002059591N1Phase 4Completed
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind trial of atorvastatin and aspirin in Cirrhosis and hepatic fibrosis (2 arms), sponsored by Zahedan University of Medical Sciences. Primary endpoints: Quality of life, Creatine kinase and 2 more. Started Dec 2023; status: completed.
02
Drugs
atorvastatinaspirin
03
Conditions
Cirrhosishepatic fibrosis
Beyond the preview
Go deeper on IRCT20231002059591N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231002059591N1.